Viatris reports Q1 adjusted EPS 67c, consensus 67c

Reports Q1 revenue $3.66B, consensus $3.69B. Viatris CEO Scott A. Smith said: “Our strong first quarter financial results demonstrate continued execution against our business fundamentals, which includes maintaining base business stability while driving new product revenue and executing on our vision for future growth. We have closed our Women’s Healthcare Business divestiture, and expect our API divestiture to close imminently. We have also closed our global collaboration with Idorsia and are already expanding and accelerating the Phase 3 development programs for both selatogrel and cenerimod in meaningful ways-all while we continue to deliver increased total shareholder return and pay down debt.”